Drugs / HP-211
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07546929 | Feb 2023 → Oct 2026 expected | type 2 diabetes mellitus | Housey Healthcare ULC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HP-211 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07546929 ↗ |
| Route | Oral | “Subjects will take 0, 1, 2 or 3 tablets of HP-211 in the morning and evening for 90 days.” NCT07546929 ↗ |